On the stock market since 2000, it operates in the world of health and science. It has 74 employees. Now — the numbers.
The company closed last year at a loss: costs ran above sales. The picture changes only if spending is reined in.
An average decline of 11% a year over the last 4 years — the most striking risk in this picture. Red columns mark years that ended in a loss.
Before the clock runs out, either sales must climb sharply or new money must come in. For now, time is on the company’s side.
angles, checked one by one.
The 4 that stand out are on screen; the rest came back neutral.
The council scores out of 10; report-card grades are out of 100.
Profit per Sale: Right now the product sells for less than it costs to make; every sale deepens the loss.
The stock trades near its peak today. For long-term holders the ride has paid off so far — though past performance guarantees nothing about the future.
The company sells $16K a year; the problem isn’t sales — it’s costs running above that number.
There is $337.1M in the vault; even if every debt were paid off, $335.8M would remain.
A loss of $76.1M against $16K in annual sales.
The price action doesn’t yet back an upward turn. Council score: 0/10.
Right now the product sells for less than it costs to make; every sale deepens the loss. Council score: 3/10.
On our five-subject report card, BLU sits behind the class. A low grade doesn’t mean “doomed” — it means “big claim, small proof.”
The takeaway: BLU is a small company that closed last year at a loss. The road back to profit runs through spending discipline.